Values of CD4+ T lymphocytes in our CIS patients at baseline were lower than we commonly found in MS patients in our laboratory and so we assumed significant augmentation in this subset during the disease progression to CDMS, but only a tendency to increase during the whole time of follow-up was found in all groups. This evidence concerns the gene CD4 and myeloid sarcoma.